NuCana plc American Depositary Share (NCNA)
NCNA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NCNA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2017 |
| SEC CIK | 0001709626 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "If there is substantial doubt about our ability to continue as a going concern in the future, it may negatively impact the trading price of our securities, have an adverse impact on our relationship with third parties with whom we do business, including our customers, vendors and employees, and could make it challenging and difficult for us to raise additional equity or debt financing to the extent needed, all of whi" | 20-F 2026-03-19 |
| Cash and burn | 24.3M GBP cash; operating cash flow -1.9M GBP a quarter. | Report 2025-12-31 |
| Shares outstanding | 4,161,971 (2025-12-31); 28,407 a year earlier; 10,475 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Edinburgh, United Kingdom | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -29.4M GBP | -7.5M GBP | 24.3M GBP | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2024 2024-12-31 | Not filed | -19.0M GBP | -19.1M GBP | 6.7M GBP | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2023 2023-12-31 | Not filed | -27.6M GBP | -26.4M GBP | 17.2M GBP | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2022 2022-12-31 | Not filed | -32.0M GBP | -23.2M GBP | 41.9M GBP | No debt tags | Needs four quarters | 20-F 2025-03-20 |
| FY 2021 2021-12-31 | Not filed | -40.5M GBP | -23.8M GBP | 60.3M GBP | No debt tags | Needs four quarters | 20-F 2024-03-20 |
| FY 2020 2020-12-31 | Not filed | -30.7M GBP | -21.6M GBP | 87.4M GBP | No debt tags | Needs four quarters | 20-F 2023-04-04 |
| FY 2019 2019-12-31 | Not filed | -21.4M GBP | -23.8M GBP | 52.0M GBP | No debt tags | Needs four quarters | 20-F 2022-04-27 |
| FY 2018 2018-12-31 | Not filed | -13.8M GBP | -12.2M GBP | 77.0M GBP | No debt tags | Needs four quarters | 20-F 2021-03-04 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in GBP.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-06-27 |
| Latest annual report | 20-F | 2026-03-19 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 283 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.5% |
| 1 month | -11.1% |
| 3 months | -37.0% |
| Year to date | -74.1% |
| 1 year | -73.3% |
| From 52-week high | -78.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| TRAW | Traws Pharma Inc. | $0.2600 | +3.59% | $4.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier